NCT00743262 · OUTCOME

Short-term Feasibility Provox Vega 22.5 French

Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice Prosthesis · Source last updated 2023-07-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Patients
Interval / dispersion: Not reported
Time frame: 3 weeks

What was measured

Number of participants in whom the voice prosthesis was considered feasible in the short-term with regards to clinical and technical aspects as judged by patient and investigator.

Groups in this outcome

Provox Vega 22.5 French

A group of laryngectomized Provox ActiValve users tested the Provox Vega 22.5 French voice prosthesis for 3 weeks.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Provox Vega 22.5 French	15

Reported measurements

Source class 1

Values in Patients · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Provox Vega 22.5 French	15	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
15

denoms

counts
group Id
OG000
value
15
units
Participants

description

Number of participants in whom the voice prosthesis was considered feasible in the short-term with regards to clinical and technical aspects as judged by patient and investigator.

groups

description
A group of laryngectomized Provox ActiValve users tested the Provox Vega 22.5 French voice prosthesis for 3 weeks.
id
OG000
title
Provox Vega 22.5 French

param Type

NUMBER

reporting Status

POSTED

time Frame

3 weeks

title

Short-term Feasibility Provox Vega 22.5 French

type

PRIMARY

unit Of Measure

Patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice